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Background:  Transcatheter aortic valve replacement (TAVR) has emerged as an alternative to medical therapy for severe aortic stenosis 
(AS); however, patient selection continues to be challenging. To date, predictive analyses have focused on surgical scores prior to TAVR 
referral or patient factors specific to those undergoing TAVR alone. We aimed to create a simple clinical composite score to be used at the 
time of referral for TAVR to help identify risk of mortality independent of treatment modality.
methods: Retrospective analysis of 397 patients with severe AS who were referred for TAVR evaluation and completed 12 months follow 
up. A composite risk score (BR2ACED) was constructed to include BNP, RDW, RVSP, albumin, creatinine, EF and diastolic relaxation 
pattern. A logistic regression model and a Cox proportional Hazards model were fit for one-year mortality and time to death to assess the 
individual predictive value of the composite score. Covariates included intervention type, age and sex.
results:  Of the 397 individuals, 44 underwent surgical aortic valve replacement, 213 underwent TAVR and 140 received conservative 
medical therapy. Mean age was 78.4 years, 45% females and 86% had an EF below 30%. In unadjusted analyses, each additional 
point increase in BR2ACED composite score was associated with increased mortality at one year for all individuals with severe AS (OR 
1.21, 95% CI 1.04-1.41, p=0.0139). After adjustment for age, sex and intervention type, each additional point increase in risk score was 
associated with increasing mortality at one year by 26% (OR 1.26, 95% CI 1.07-1.48, p=0.006). In secondary analyses each additional 
point increase in risk score was associated with 1.22 times shorter duration to death (95% CI 1.07-1.39, p=0.0109). Additionally, when the 
cohort was restricted to the TAVR and medical therapy group alone, the association between composite score and increased mortality (OR 
1.28, 95% CI 1.08-1.51, p=0.0047) and a shorter time to death (HR 1.52 95% CI 1.16-2.01, p=0.0028) remained significant.
conclusion:  The addition of BR2ACED composite risk score to clinical evaluation at the time of referral for TAVR improves mortality risk 
assessment.
